Grifols launches FESILTY fibrinogen concentrate in the US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
June 15, 2026 8:00 AM EDTThe new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.
FESILTY complements Grifols bleeding management portfolio, expanding therapeutic options for patients.
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the... More
